Stock search

Ticker or company name

IQVIA

IQV · NYSE · Life Sciences Tools & Services

$264,73Down −0,39 (−0,15%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$43,2 bn
Div. yield
—
Year to date
+17,6%
52 weeks: $154,50$284,50

Ratio score

72/100
Ratio would consider buying

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

5 ✓ · 3 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM31,330,937,9
Forward P/E20,2—29,5
PEG2,5—3,7
P/S2,52,56,6
EV/EBITDA16,816,329,9
P/FCF21,0—38,7
P/B6,66,25,4

Industry median — across 11 profitable companies in “Life Sciences Tools & Services” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 26 analysts

Buy
24
Hold
2
Sell
0

Beat the EPS forecast in 3 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20263,313,34Up +0,9%
Q2 20263,063,15Up +2,9%
Q1 20262,852,90Up +1,9%
Q4 20253,433,42Down −0,3%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue4,43 bn4,37 bn4,15 bn4,36 bn4,10 bn4,02 bn3,83 bn3,96 bn3,90 bn3,81 bn3,74 bn3,87 bn
EPS2,101,531,612,981,931,541,402,411,551,971,562,53
Margin7,9%5,9%6,6%11,8%8,1%6,6%6,5%11,0%7,3%9,5%7,7%12,1%
FCF667 m360 m491 m561 m772 m292 m426 m721 m571 m445 m377 m568 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $39,3 m.

NameAmountSharesPrice
sherbet eric9 Nov 2026 · sale$1,24 m4 446$278,83
berkshire james g.2 Sep 2026 · sale$697 2282 668$261,33
staub w richard3 Aug 2026 · sale$1,28 m5 500$232,68
patel bhavik31 Jul 2026 · sale$436 4261 855$235,27
sherbet eric29 Jul 2026 · sale$1,25 m5 000$249,16
cherofsky keriann29 Jul 2026 · sale$136 827558$245,21
bousbib ari29 Jul 2026 · sale$13,0 m53 191$244,78
bousbib ari29 Jul 2026 · sale$10,8 m44 039$246,08
bousbib ari29 Jul 2026 · sale$1,13 m4 584$246,85
bousbib ari29 Jul 2026 · sale$1,10 m4 465$247,10
bousbib ari18 Dec 2025 · sale$8,13 m36 564$222,43

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Life Sciences Tools & Services
Exchange
NYSE
Country
US
IPO date
9 May 2013

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
WATWaters Corporation$453,4229would not consider269,0—1,8%
AAgilent Technologies$172,9278would consider34,1+8,6%19,5%
MTDMettler Toledo$1 727,2663would watch36,5+6,5%22,2%
ILMNIllumina, Inc.$198,0075would consider33,6+5,8%19,7%
WSTWest Pharmaceutical Services$417,8083would consider45,5+12,6%18,8%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.